The introduction of amivantamab represents a significant development for people battling cancers exhibiting c-MET overexpression. This novel therapeutic, a selective blocker of both MET kinase and human epidermal https://cormacvhbt007375.wikimidpoint.com/7071657/amivantamab_a_potential_solution_for_c_met_driven_growths